الخلاصة

Carbapenem antibiotics assume a basic parts in the treatment of serious nosocomial diseases brought on by microorganisms with decreased susceptibility to different antimicrobials. Shockingly, the prevalence of carbapenem- resistant bacteria has all the earmarks of being expanding and treatment choices for infections brought on via carbapenemresistance bacteria are constrained and connected with high death rates. This study was directed to decide the event of carbapenemases (blaIMP and blaSIM) producing A. Baumannii isolates acquired from Babylon hospitals. Isolates were recognized by biochemical tests and more affirmed utilizing API 20E system. Carbapenem susceptibility was measured by utilizing disks diffusion test. Phenotypic identification of carbapenemase was performed utilizing the imipenem-EDTA disk and modified Hodge tests. At that point isolateswere subjected to monoplex PCR focusing on blaIMP and blaSIM qualities. Ten (0.76%) A. baumannii isolates were recuperated from clinical specimens. One (10%) isolate was observed to be imipenem and meropenem resistant (MIC > 512 μg/ml). Six isolates (60%) gave positive result with the imipenem-EDTA double disk synergy test and modified Hodge test. PCR tests indicated five isolates(50%) were harbored blaIMP genes and six (60%) isolates were harbored blaSIM genes. The present discoveries uncovered to rise of blaIMP and blaSIM carbapenemase-producing A. baumannii clinical disengages in Babylon hospitals. Keywords: blaIMP and blaSIM Genes, Clinical Isolates of Acinetobacter baumannii.